Ultragenyx Pharmaceutical reported $86.65M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 123.66M 2.71M Jun/2025
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
Alnylam Pharmaceuticals USD 323.31M 83.36M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Insmed USD 76.44M 71.11M Jun/2025
Ionis Pharmaceuticals USD 90.6M 14.6M Jun/2025
Kyowa Hakko Kirin JPY 40.78B 1.26B Jun/2025
MacroGenics USD 9.3M 18.51M Jun/2025
Moderna USD 230M 18M Jun/2025
Neurocrine Biosciences USD 286.3M 9.8M Jun/2025
PTC Therapeutics USD 85.26M 76.66M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
Ultragenyx Pharmaceutical USD 86.65M 1.15M Jun/2025
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025